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As of  2011, cancer was the leading 
cause of  death in the United States, 
second only to heart disease. Cancer is 
often referred to as being “immortal” 
because of  its ability to divide a seemingly 
infinite amount of  times. Normal cells 
are limited in the number of  times they 
can divide by the caps on the ends of  
their chromosomes, called telomeres. 
These caps are supposed to become 
degraded over time, signaling the cell 
to die when they become too short. As 
cancer continues to become an ever-
increasing threat to human health, the 
race is on to find an effective telomerase 
inhibitor. If  telomerase is inhibited, the 
telomeres of  cancer cells can no longer be 
elongated. Stripped of  their immortality, 
cancer cells will eventually undergo 
apoptosis, or controlled cell death. 
This inhibitor has to be able to destroy 
cancer cells while leaving healthy cells 
unharmed. Research has uncovered that 
the molecular structure of  a compound 
known as BIBR 1532 has proven to be 
an effective telomerase inhibitor. Current 
research has shown that BIBR 1532 
inhibits telomerase by preventing it from 
extending the copied strand any further 
than the length of  the original  
strand of  DNA. 
Research has not yet discovered what 
portion of  BIBR 1532 causes it to 
be such a good telomerase inhibitor, 
though several theories do exist. The 
most popular theory, supported by past 
research, is that three structures present 
in the BIBR molecule contribute to its 
efficacy: an aromatic ring containing a 
carboxylic acid and a conjugated amine 
group. This is the theory on which my 
current research is based upon and 
served as the basis for the synthesized 
compounds. Three compounds were 
made via the synthesis of  cinnamic 
acid and contained the aforementioned 
substructures found in BIBR 1532.  The 
basic skeleton of  the chemical structure 
was created from cinnamic acid, due to 
its natural ability to inhibit telomerase. 
Using the reactive properties of  cinnamic 
acid, several different substituents were 
added while maintaining the three key 
structures. The Schotten-Baumann 
protocol was utilized to synthesize 
the final product, the purity of  which 
was tested using HNMR and CNMR 
techniques. The results of  this experiment 
were three novel chemical compounds 
that each contains an aromatic ring, a 
carboxylic acid, and a conjugated amine 
group. These compounds also possess the 
natural anticancer properties of   
cinnamic acid. 
These three compounds are currently 
undergoing testing for telomerase 
inhibition using the Telomerase Repeat 
Amplification Protocol assay. The 
compounds will be tested on prostate 
cancer cell lines, in order to determine 
whether my compounds are active 
against telomerase. Their efficacy will be 
compared against BIBR 1532 itself, as 
well as other known telomerase inhibitors. 
The compounds will also be tested to 
determine if  it has the ability to destroy 
cancer cells, while leaving healthy cells 
untouched.  If  one of  these compounds 
is found to be more effective at fighting 
cancer then BIBR 1532, it would open 
doors to a newer and safer drug 
 treatment program. 
The structure of  BIBR 1532
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